<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20240628180826&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20240628180826&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 28 Jun 2024 22:08:28 +0000</lastbuilddate>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38940005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: After adjustment for potential confounding factors, presence of AF was associated with higher mortality than no AF in our cohort of patients with cardiac implantable electronic devices. Among those with AF, nonparoxysmal AF was associated with the greatest risk of mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.124.069757. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Current estimates of atrial fibrillation (AF)-associated mortality rely on claims- or clinical-derived diagnoses of AF, limit AF to a binary entity, or are confounded by comorbidities. The objective of the present study is to assess the association between device-recognized AF and mortality among patients with cardiac implantable electronic devices capable of sensitive and continuous atrial arrhythmia detection. Secondary outcomes include relative mortality among cohorts with no AF, paroxysmal AF, persistent AF, and permanent AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the deidentified Optum Clinformatics US claims database (2015 to 2020) linked to the Medtronic CareLink database, we identified individuals with a cardiac implantable electronic device who transmitted data ≥6 months after implantation. AF burden was assessed during the first 6 months after implantation (baseline period). Subsequent mortality, assessed from claims data, was compared between patients with and those without AF, with adjustment for age, geographic region, insurance type, Charlson Comorbidity Index, and implantation year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 21 391 patients (age, 72.9±10.9 years; 56.3% male) analyzed, 7798 (36.5%) had device-recognized AF. During a mean of 22.4±12.9 months (median, 20.1 [12.8-29.7] months) of follow-up, the overall incidence of mortality was 13.5%. Patients with AF had higher adjusted all-cause mortality than patients without AF (hazard ratio, 1.29 [95% CI, 1.20-1.39]; <i>P</i>&lt;0.001). Among those with AF, patients with nonparoxysmal AF had the greatest risk of mortality (persistent AF versus paroxysmal AF: hazard ratio, 1.36 [95% CI, 1.18-1.58]; <i>P</i>&lt;.001; permanent AF versus paroxysmal AF: hazard ratio, 1.23 [95% CI, 1.14-1.34]; <i>P</i>&lt;.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: After adjustment for potential confounding factors, presence of AF was associated with higher mortality than no AF in our cohort of patients with cardiac implantable electronic devices. Among those with AF, nonparoxysmal AF was associated with the greatest risk of mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38940005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38940005</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069757>10.1161/CIRCULATIONAHA.124.069757</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38940005</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Graham Peigh</dc:creator>
<dc:creator>Jiani Zhou</dc:creator>
<dc:creator>Sarah C Rosemas</dc:creator>
<dc:creator>Anthony I Roberts</dc:creator>
<dc:creator>Colleen Longacre</dc:creator>
<dc:creator>Katherine Trinh</dc:creator>
<dc:creator>Tanvi Nayak</dc:creator>
<dc:creator>Dana Soderlund</dc:creator>
<dc:creator>Rod S Passman</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices</dc:title>
<dc:identifier>pmid:38940005</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069757</dc:identifier>
</item>
<item>
<title>Waitlist Outcomes for Pediatric Heart Transplantation in the Current Era: An Analysis of the Pediatric Heart Transplant Society Database</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38939965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: There is significant variability in WM among status-1A patients. Potential refinements to current allocation system should factor in the increased WM risk we identified in patients supported by extracorporeal membrane oxygenation or mechanical ventilation, single ventricle congenital heart disease on VAD support and small children with congenital heart disease, restrictive cardiomyopathy, or hypertrophic cardiomyopathy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.123.068189. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Waitlist mortality (WM) remains elevated in pediatric heart transplantation. Allocation policy is a potential tool to help improve WM. This study aims to identify patients at highest risk for WM to potentially inform future allocation policy changes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Pediatric Heart Transplant Society database was queried for patients &lt;18 years of age indicated for heart transplantation between January 1, 2010 to December 31, 2021. <i>Waitlist mortality</i> was defined as death while awaiting transplant or removal from the waitlist due to clinical deterioration. Because WM is low after the first year, analysis was limited to the first 12 months on the heart transplant list. Kaplan-Meier analysis and log-rank testing was conducted to compare unadjusted survival between groups. Cox proportional hazard models were created to determine risk factors for WM. Subgroup analysis was performed for status 1A patients based on body surface area (BSA) at time of listing, cardiac diagnosis, and presence of mechanical circulatory support.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total 5974 children met study criteria of which 3928 were status 1A, 1012 were status 1B, 963 were listed status 2, and 65 were listed status 7. Because of the significant burden of WM experienced by 1A patients, further analysis was performed in only patients indicated as 1A. Within that group of patients, those with smaller size and lower eGFR had higher WM, whereas those patients without congenital heart disease or support from a ventricular assist device (VAD) at time of listing had decreased WM. In the smallest size cohort, cardiac diagnoses other than dilated cardiomyopathy were risk factors for WM. Previous cardiac surgery was a risk factor in the 0.3 to 0.7 m<sup>2</sup> and >;0.7 m<sup>2</sup> BSA groups. VAD support was associated with lower WM other than in the single ventricle cohort, where VAD was associated with higher WM. Extracorporeal membrane oxygenation and mechanical ventilation were associated with increased risk of WM in all cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: There is significant variability in WM among status-1A patients. Potential refinements to current allocation system should factor in the increased WM risk we identified in patients supported by extracorporeal membrane oxygenation or mechanical ventilation, single ventricle congenital heart disease on VAD support and small children with congenital heart disease, restrictive cardiomyopathy, or hypertrophic cardiomyopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38939965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38939965</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068189>10.1161/CIRCULATIONAHA.123.068189</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38939965</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ryan J Butts</dc:creator>
<dc:creator>Leah Toombs</dc:creator>
<dc:creator>James K Kirklin</dc:creator>
<dc:creator>Kurt R Schumacher</dc:creator>
<dc:creator>Jennifer Conway</dc:creator>
<dc:creator>Shawn C West</dc:creator>
<dc:creator>Scott Auerbach</dc:creator>
<dc:creator>Neha Bansal</dc:creator>
<dc:creator>Hong Zhao</dc:creator>
<dc:creator>Ryan S Cantor</dc:creator>
<dc:creator>Deipanjan Nandi</dc:creator>
<dc:creator>David M Peng</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Waitlist Outcomes for Pediatric Heart Transplantation in the Current Era: An Analysis of the Pediatric Heart Transplant Society Database</dc:title>
<dc:identifier>pmid:38939965</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068189</dc:identifier>
</item>
<item>
<title>Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38939955/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Mexiletine significantly shortens cardiac repolarization in LQT2 human induced pluripotent stem cells, in the LQT2 rabbit model, and in the majority of patients with LQT2. Furthermore, mexiletine showed antiarrhythmic efficacy. Mexiletine should therefore be considered a valid therapeutic option to be added to conventional therapies in higher-risk patients with LQT2.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.124.068959. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite major advances in the clinical management of long QT syndrome, some patients are not fully protected by beta-blocker therapy. Mexiletine is a well-known sodium channel blocker, with proven efficacy in patients with sodium channel-mediated long QT syndrome type 3. Our aim was to evaluate the efficacy of mexiletine in long QT syndrome type 2 (LQT2) using cardiomyocytes derived from patient-specific human induced pluripotent stem cells, a transgenic LQT2 rabbit model, and patients with LQT2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Heart rate-corrected field potential duration, a surrogate for QTc, was measured in human induced pluripotent stem cells from 2 patients with LQT2 (KCNH2-p.A561V, KCNH2-p.R366X) before and after mexiletine using a multiwell multi-electrode array system. Action potential duration at 90% repolarization (APD<sub>90</sub>) was evaluated in cardiomyocytes isolated from transgenic LQT2 rabbits (KCNH2-p.G628S) at baseline and after mexiletine application. Mexiletine was given to 96 patients with LQT2. Patients were defined as responders in the presence of a QTc shortening ≥40 ms. Antiarrhythmic efficacy of mexiletine was evaluated by a Poisson regression model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After acute treatment with mexiletine, human induced pluripotent stem cells from both patients with LQT2 showed a significant shortening of heart rate-corrected field potential duration compared with dimethyl sulfoxide control. In cardiomyocytes isolated from LQT2 rabbits, acute mexiletine significantly shortened APD<sub>90</sub> (∆APD shortening 113 ms), indicating a strong mexiletine-mediated shortening across different LQT2 model systems. Mexiletine was given to 96 patients with LQT2 either chronically (n=60) or after the acute oral drug test (n=36): 65% of the patients taking mexiletine only chronically and 75% of the patients who performed the acute oral test were responders. There was a significant correlation between basal QTc and ∆QTc during the test (<i>r</i>= -0.8; <i>P</i>&lt;0.001). The oral drug test correctly predicted long-term effect in 93% of the patients. Mexiletine reduced the mean yearly event rate from 0.10 (95% CI, 0.07-0.14) to 0.04 (95% CI, 0.02-0.08), with an incidence rate ratio of 0.40 (95% CI, 0.16-0.84), reflecting a 60% reduction in the event rate (<i>P</i>=0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Mexiletine significantly shortens cardiac repolarization in LQT2 human induced pluripotent stem cells, in the LQT2 rabbit model, and in the majority of patients with LQT2. Furthermore, mexiletine showed antiarrhythmic efficacy. Mexiletine should therefore be considered a valid therapeutic option to be added to conventional therapies in higher-risk patients with LQT2.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38939955/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38939955</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068959>10.1161/CIRCULATIONAHA.124.068959</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38939955</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Lia Crotti</dc:creator>
<dc:creator>Raquel Neves</dc:creator>
<dc:creator>Federica Dagradi</dc:creator>
<dc:creator>Giulia Musu</dc:creator>
<dc:creator>Federica Giannetti</dc:creator>
<dc:creator>J Martijn Bos</dc:creator>
<dc:creator>Miriam Barbieri</dc:creator>
<dc:creator>Paolo Cerea</dc:creator>
<dc:creator>Fulvio L F Giovenzana</dc:creator>
<dc:creator>Margherita Torchio</dc:creator>
<dc:creator>Manuela Mura</dc:creator>
<dc:creator>Massimiliano Gnecchi</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:creator>Angelo Auricchio</dc:creator>
<dc:creator>Luca Sala</dc:creator>
<dc:creator>Katja E Odening</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Peter J Schwartz</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients</dc:title>
<dc:identifier>pmid:38939955</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068959</dc:identifier>
</item>
<item>
<title>Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38939948/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The PASSION trial, terminated prematurely due to study medication supply disruption, does not support tadalafil use in patients with heart failure with preserved ejection fraction and combined postcapillary and precapillary pulmonary hypertension, with potential safety concerns and no observed benefits in primary and secondary end points.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.124.069340. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: We assessed the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, in patients with heart failure with preserved ejection fraction and combined postcapillary and precapillary pulmonary hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the double-blind PASSION study (Phosphodiesterase-5 Inhibition in Patients With Heart Failure With Preserved Ejection Fraction and Combined Post- and Pre-Capillary Pulmonary Hypertension), patients with heart failure with preserved ejection fraction and combined postcapillary and precapillary pulmonary hypertension were randomized 1:1 to receive tadalafil at a target dose of 40 mg or placebo. The primary end point was the time to the first composite event of adjudicated heart failure hospitalization or all-cause death. Secondary end points included all-cause mortality and improvements in New York Heart Association functional class or ≥10% improvement in 6-minute walking distance from baseline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Initially targeting 372 patients, the study was terminated early because of disruption in study medication supply. At that point, 125 patients had been randomized (placebo: 63; tadalafil: 62,). Combined primary end-point events occurred in 20 patients (32%) assigned to placebo and 17 patients (27%) assigned to tadalafil (hazard ratio, 1.02 [95% CI, 0.52-2.01]; <i>P</i>=0.95). There was a possible signal of higher all-cause mortality in the tadalafil group (hazard ratio, 5.10 [95% CI, 1.10-23.69]; <i>P</i>=0.04). No significant between-group differences were observed in other secondary end points. Serious adverse events occurred in 29 participants (48%) in the tadalafil group and 35 (56%) in the placebo group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The PASSION trial, terminated prematurely due to study medication supply disruption, does not support tadalafil use in patients with heart failure with preserved ejection fraction and combined postcapillary and precapillary pulmonary hypertension, with potential safety concerns and no observed benefits in primary and secondary end points.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrialsregister.eu/; Unique identifier: 2017-003688-37. URL: https://drks.de; Unique identifier: DRKS -DRKS00014595.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38939948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38939948</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069340>10.1161/CIRCULATIONAHA.124.069340</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38939948</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Marius M Hoeper</dc:creator>
<dc:creator>Britta Oerke</dc:creator>
<dc:creator>Max Wissmüller</dc:creator>
<dc:creator>Hanno Leuchte</dc:creator>
<dc:creator>Christian Opitz</dc:creator>
<dc:creator>Michael Halank</dc:creator>
<dc:creator>Hans-Juergen Seyfarth</dc:creator>
<dc:creator>Stephan Baldus</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Hossein-Ardeschir Ghofrani</dc:creator>
<dc:creator>Stavros Konstantinides</dc:creator>
<dc:creator>Karen M Olsson</dc:creator>
<dc:creator>Rolf Wachter</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Behnaz Aminossadati</dc:creator>
<dc:creator>Stephan Rosenkranz</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study</dc:title>
<dc:identifier>pmid:38939948</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069340</dc:identifier>
</item>
<item>
<title>Anti-Arrhythmic Mechanisms of Epidural Blockade After Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38939925/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TEA does not compromise right ventricular function in infarcted hearts. Its antiarrhythmic mechanisms are mediated by increases in ventricular effective refractory period and ARIs, decreases in S(max), and reductions in border zone electrophysiological heterogeneities. TEA improves parasympathetic function, which may independently underlie some of its observed antiarrhythmic mechanisms. This study provides novel insights into the antiarrhythmic mechanisms of TEA while highlighting...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 28. doi: 10.1161/CIRCRESAHA.123.324058. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Thoracic epidural anesthesia (TEA) has been shown to reduce the burden of ventricular tachycardia in small case series of patients with refractory ventricular tachycardia and cardiomyopathy. However, its electrophysiological and autonomic effects in diseased hearts remain unclear, and its use after myocardial infarction is limited by concerns for potential right ventricular dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Myocardial infarction was created in Yorkshire pigs (N=22) by left anterior descending coronary artery occlusion. Six weeks after myocardial infarction, an epidural catheter was placed at the C7-T1 vertebral level for injection of 2% lidocaine. Right and left ventricular hemodynamics were recorded using Millar pressure-conductance catheters, and ventricular activation recovery intervals (ARIs), a surrogate of action potential durations, by a 56-electrode sock and 64-electrode basket catheter. Hemodynamics and ARIs, baroreflex sensitivity and intrinsic cardiac neural activity, and ventricular effective refractory periods and slope of restitution (S<sub>max</sub>) were assessed before and after TEA. Ventricular tachyarrhythmia inducibility was assessed by programmed electrical stimulation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: TEA reduced inducibility of ventricular tachyarrhythmias by 70%. TEA did not affect right ventricular-systolic pressure or contractility although left ventricular-systolic pressure and contractility decreased modestly. Global and regional ventricular ARIs increased, including in scar and border zone regions post-TEA. TEA reduced ARI dispersion specifically in border zone regions. Ventricular effective refractory periods prolonged significantly at critical sites of arrhythmogenesis, and S<sub>max</sub> was reduced. Interestingly, TEA significantly improved cardiac vagal function, as measured by both baroreflex sensitivity and intrinsic cardiac neural activity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TEA does not compromise right ventricular function in infarcted hearts. Its antiarrhythmic mechanisms are mediated by increases in ventricular effective refractory period and ARIs, decreases in S<sub>max</sub>, and reductions in border zone electrophysiological heterogeneities. TEA improves parasympathetic function, which may independently underlie some of its observed antiarrhythmic mechanisms. This study provides novel insights into the antiarrhythmic mechanisms of TEA while highlighting its applicability to the clinical setting.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38939925/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38939925</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324058>10.1161/CIRCRESAHA.123.324058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38939925</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jonathan D Hoang</dc:creator>
<dc:creator>Valerie Y H van Weperen</dc:creator>
<dc:creator>Ki-Woon Kang</dc:creator>
<dc:creator>Neil R Jani</dc:creator>
<dc:creator>Mohammed A Swid</dc:creator>
<dc:creator>Christopher A Chan</dc:creator>
<dc:creator>Zulfiqar Ali Lokhandwala</dc:creator>
<dc:creator>Robert L Lux</dc:creator>
<dc:creator>Marmar Vaseghi</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Anti-Arrhythmic Mechanisms of Epidural Blockade After Myocardial Infarction</dc:title>
<dc:identifier>pmid:38939925</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324058</dc:identifier>
</item>
<item>
<title>Transcatheter treatment of pure aortic regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38937627/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 27. doi: 10.1038/s41569-024-01059-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38937627/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38937627</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01059-1>10.1038/s41569-024-01059-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38937627</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Barbanti</dc:creator>
<dc:creator>Giulia Laterra</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Transcatheter treatment of pure aortic regurgitation</dc:title>
<dc:identifier>pmid:38937627</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01059-1</dc:identifier>
</item>
<item>
<title>Autoimmune diseases and atherosclerotic cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38937626/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>Autoimmune diseases are associated with a dramatically increased risk of atherosclerotic cardiovascular disease and its clinical manifestations. The increased risk is consistent with the notion that atherogenesis is modulated by both protective and disease-promoting immune mechanisms. Notably, traditional cardiovascular risk factors such as dyslipidaemia and hypertension alone do not explain the increased risk of cardiovascular disease associated with autoimmune diseases. Several mechanisms have...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 27. doi: 10.1038/s41569-024-01045-7. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Autoimmune diseases are associated with a dramatically increased risk of atherosclerotic cardiovascular disease and its clinical manifestations. The increased risk is consistent with the notion that atherogenesis is modulated by both protective and disease-promoting immune mechanisms. Notably, traditional cardiovascular risk factors such as dyslipidaemia and hypertension alone do not explain the increased risk of cardiovascular disease associated with autoimmune diseases. Several mechanisms have been implicated in mediating the autoimmunity-associated cardiovascular risk, either directly or by modulating the effect of other risk factors in a complex interplay. Aberrant leukocyte function and pro-inflammatory cytokines are central to both disease entities, resulting in vascular dysfunction, impaired resolution of inflammation and promotion of chronic inflammation. Similarly, loss of tolerance to self-antigens and the generation of autoantibodies are key features of autoimmunity but are also implicated in the maladaptive inflammatory response during atherosclerotic cardiovascular disease. Therefore, immunomodulatory therapies are potential efficacious interventions to directly reduce the risk of cardiovascular disease, and biomarkers of autoimmune disease activity could be relevant tools to stratify patients with autoimmunity according to their cardiovascular risk. In this Review, we discuss the pathophysiological aspects of the increased cardiovascular risk associated with autoimmunity and highlight the many open questions that need to be answered to develop novel therapies that specifically address this unmet clinical need.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38937626/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38937626</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01045-7>10.1038/s41569-024-01045-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38937626</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Florentina Porsch</dc:creator>
<dc:creator>Christoph J Binder</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Autoimmune diseases and atherosclerotic cardiovascular disease</dc:title>
<dc:identifier>pmid:38937626</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01045-7</dc:identifier>
</item>
<item>
<title>Preclinical proof of principle for orally delivered Th17 antagonist miniproteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38936360/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>Interleukin (IL)-23 and IL-17 are well-validated therapeutic targets in autoinflammatory diseases. Antibodies targeting IL-23 and IL-17 have shown clinical efficacy but are limited by high costs, safety risks, lack of sustained efficacy, and poor patient convenience as they require parenteral administration. Here, we present designed miniproteins inhibiting IL-23R and IL-17 with antibody-like, low picomolar affinities at a fraction of the molecular size. The minibinders potently block cell...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 23:S0092-8674(24)00631-7. doi: 10.1016/j.cell.2024.05.052. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Interleukin (IL)-23 and IL-17 are well-validated therapeutic targets in autoinflammatory diseases. Antibodies targeting IL-23 and IL-17 have shown clinical efficacy but are limited by high costs, safety risks, lack of sustained efficacy, and poor patient convenience as they require parenteral administration. Here, we present designed miniproteins inhibiting IL-23R and IL-17 with antibody-like, low picomolar affinities at a fraction of the molecular size. The minibinders potently block cell signaling in vitro and are extremely stable, enabling oral administration and low-cost manufacturing. The orally administered IL-23R minibinder shows efficacy better than a clinical anti-IL-23 antibody in mouse colitis and has a favorable pharmacokinetics (PK) and biodistribution profile in rats. This work demonstrates that orally administered de novo-designed minibinders can reach a therapeutic target past the gut epithelial barrier. With high potency, gut stability, and straightforward manufacturability, de novo-designed minibinders are a promising modality for oral biologics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38936360/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38936360</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.052>10.1016/j.cell.2024.05.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38936360</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephanie Berger</dc:creator>
<dc:creator>Franziska Seeger</dc:creator>
<dc:creator>Ta-Yi Yu</dc:creator>
<dc:creator>Merve Aydin</dc:creator>
<dc:creator>Huilin Yang</dc:creator>
<dc:creator>Daniel Rosenblum</dc:creator>
<dc:creator>Laure Guenin-Macé</dc:creator>
<dc:creator>Caleb Glassman</dc:creator>
<dc:creator>Lauren Arguinchona</dc:creator>
<dc:creator>Catherine Sniezek</dc:creator>
<dc:creator>Alyssa Blackstone</dc:creator>
<dc:creator>Lauren Carter</dc:creator>
<dc:creator>Rashmi Ravichandran</dc:creator>
<dc:creator>Maggie Ahlrichs</dc:creator>
<dc:creator>Michael Murphy</dc:creator>
<dc:creator>Ingrid Swanson Pultz</dc:creator>
<dc:creator>Alex Kang</dc:creator>
<dc:creator>Asim K Bera</dc:creator>
<dc:creator>Lance Stewart</dc:creator>
<dc:creator>K Christopher Garcia</dc:creator>
<dc:creator>Shruti Naik</dc:creator>
<dc:creator>Jamie B Spangler</dc:creator>
<dc:creator>Florian Beigel</dc:creator>
<dc:creator>Matthias Siebeck</dc:creator>
<dc:creator>Roswitha Gropp</dc:creator>
<dc:creator>David Baker</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Preclinical proof of principle for orally delivered Th17 antagonist miniproteins</dc:title>
<dc:identifier>pmid:38936360</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.052</dc:identifier>
</item>
<item>
<title>Amplification editing enables efficient and precise duplication of DNA from short sequence to megabase and chromosomal scale</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38936359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>Duplication is a foundation of molecular evolution and a driver of genomic and complex diseases. Here, we develop a genome editing tool named Amplification Editing (AE) that enables programmable DNA duplication with precision at chromosomal scale. AE can duplicate human genomes ranging from 20 bp to 100 Mb, a size comparable to human chromosomes. AE exhibits activity across various cell types, encompassing diploid, haploid, and primary cells. AE exhibited up to 73.0% efficiency for 1 Mb and 3.4%...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 19:S0092-8674(24)00637-8. doi: 10.1016/j.cell.2024.05.056. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Duplication is a foundation of molecular evolution and a driver of genomic and complex diseases. Here, we develop a genome editing tool named Amplification Editing (AE) that enables programmable DNA duplication with precision at chromosomal scale. AE can duplicate human genomes ranging from 20 bp to 100 Mb, a size comparable to human chromosomes. AE exhibits activity across various cell types, encompassing diploid, haploid, and primary cells. AE exhibited up to 73.0% efficiency for 1 Mb and 3.4% for 100 Mb duplications, respectively. Whole-genome sequencing and deep sequencing of the junctions of edited sequences confirm the precision of duplication. AE can create chromosomal microduplications within disease-relevant regions in embryonic stem cells, indicating its potential for generating cellular and animal models. AE is a precise and efficient tool for chromosomal engineering and DNA duplication, broadening the landscape of precision genome editing from an individual genetic locus to the chromosomal scale.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38936359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38936359</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.056>10.1016/j.cell.2024.05.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38936359</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ruiwen Zhang</dc:creator>
<dc:creator>Zhou He</dc:creator>
<dc:creator>Yajing Shi</dc:creator>
<dc:creator>Xiangkun Sun</dc:creator>
<dc:creator>Xinyu Chen</dc:creator>
<dc:creator>Guoquan Wang</dc:creator>
<dc:creator>Yizhou Zhang</dc:creator>
<dc:creator>Pan Gao</dc:creator>
<dc:creator>Ying Wu</dc:creator>
<dc:creator>Shuhan Lu</dc:creator>
<dc:creator>Junyi Duan</dc:creator>
<dc:creator>Shangwu Sun</dc:creator>
<dc:creator>Na Yang</dc:creator>
<dc:creator>Wei Fan</dc:creator>
<dc:creator>Kaitao Zhao</dc:creator>
<dc:creator>Bei Yang</dc:creator>
<dc:creator>Yuchen Xia</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:creator>Ying Zhang</dc:creator>
<dc:creator>Hao Yin</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Amplification editing enables efficient and precise duplication of DNA from short sequence to megabase and chromosomal scale</dc:title>
<dc:identifier>pmid:38936359</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.056</dc:identifier>
</item>
<item>
<title>Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38935554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 27:ehae365. doi: 10.1093/eurheartj/ehae365. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38935554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38935554</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae365>10.1093/eurheartj/ehae365</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38935554</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Emma Svennberg</dc:creator>
<dc:creator>Søren Z Diederichsen</dc:creator>
<dc:creator>Harry J G M Crijns</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>Isabelle C Van Gelder</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation</dc:title>
<dc:identifier>pmid:38935554</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae365</dc:identifier>
</item>
<item>
<title>Associations of Urban Blue and Green Spaces With Coronary Artery Calcification in Black Individuals and Disadvantaged Neighborhoods</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38934130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Longitudinally, shorter distance to a river and greater green space cover were associated with less CAC among Black participants and those in deprived neighborhoods. Shorter distance to a park was associated with increased odds of CAC among participants in deprived neighborhoods. Black participants residing in more deprived neighborhoods showed lower odds of CAC in association with greater exposure to river and green space cover.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 27. doi: 10.1161/CIRCULATIONAHA.123.067992. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Proximity to urban blue and green spaces has been associated with improved cardiovascular health; however, few studies have examined the role of race and socioeconomic status in these associations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data were from the CARDIA study (Coronary Artery Risk Development in Young Adults). We included longitudinal measurements (1985-1986 to 2010-2011) of blue and green spaces, including percentage of blue space cover, distance to the nearest river, green space cover, and distance to the nearest major park. Presence of coronary artery calcification (CAC) was measured with noncontrast cardiac computed tomography in 2010 to 2011. The associations of blue and green spaces with CAC were assessed with generalized estimating equation regression with adjustment for demographics, individual and neighborhood socioeconomic status, health-related behaviors, and other health conditions. We conducted stratified analyses by race and neighborhood deprivation score to investigate whether the association varied according to social determinants of health.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analytic sample included 1365 Black and 1555 White participants with a mean±SD age of 50.1±3.6 years. Among Black participants, shorter distance to a river and greater green space cover were associated with lower odds of CAC (per interquartile range decrease [1.45 km] to the river: odds ratio [OR], 0.90 [95% CI, 0.84-0.96]; per 10%-point increase of green space cover: OR, 0.85 [95% CI, 0.75-0.95]). Among participants in deprived neighborhoods, greater green space cover was associated with lower odds of CAC (per a 10%-point increase: OR, 0.89 [95% CI, 0.80-0.99]), whereas shorter distance to the park was associated with higher odds of CAC (per an interquartile range decrease [5.3 km]: OR, 1.07 [95% CI, 1.00-1.15]). Black participants in deprived neighborhoods had lower odds of CAC with shorter distance to a river (per an interquartile range decrease: OR, 0.90 [95% CI, 0.82-0.98]) and greater green space cover (per a 10%-point increase: OR, 0.85 [95% CI, 0.75-0.97]). There was no statistical interaction between the blue and green spaces and race or neighborhood characteristics in association with CAC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Longitudinally, shorter distance to a river and greater green space cover were associated with less CAC among Black participants and those in deprived neighborhoods. Shorter distance to a park was associated with increased odds of CAC among participants in deprived neighborhoods. Black participants residing in more deprived neighborhoods showed lower odds of CAC in association with greater exposure to river and green space cover.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38934130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38934130</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067992>10.1161/CIRCULATIONAHA.123.067992</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38934130</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Kyeezu Kim</dc:creator>
<dc:creator>Brian T Joyce</dc:creator>
<dc:creator>Yinan Zheng</dc:creator>
<dc:creator>Drew R Nannini</dc:creator>
<dc:creator>Jun Wang</dc:creator>
<dc:creator>Penny Gordon-Larsen</dc:creator>
<dc:creator>Ankeet Bhatt</dc:creator>
<dc:creator>Kelley Gabriel</dc:creator>
<dc:creator>James M Shikany</dc:creator>
<dc:creator>Ming Hu</dc:creator>
<dc:creator>Aimin Chen</dc:creator>
<dc:creator>Orna Reges</dc:creator>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:creator>Kai Zhang</dc:creator>
<dc:creator>Lifang Hou</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Associations of Urban Blue and Green Spaces With Coronary Artery Calcification in Black Individuals and Disadvantaged Neighborhoods</dc:title>
<dc:identifier>pmid:38934130</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067992</dc:identifier>
</item>
<item>
<title>Improving Outcomes After Post-Cardiac Arrest Brain Injury: A Scientific Statement From the International Liaison Committee on Resuscitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38934122/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>This scientific statement presents a conceptual framework for the pathophysiology of post-cardiac arrest brain injury, explores reasons for previous failure to translate preclinical data to clinical practice, and outlines potential paths forward. Post-cardiac arrest brain injury is characterized by 4 distinct but overlapping phases: ischemic depolarization, reperfusion repolarization, dysregulation, and recovery and repair. Previous research has been challenging because of the limitations of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 27. doi: 10.1161/CIR.0000000000001219. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This scientific statement presents a conceptual framework for the pathophysiology of post-cardiac arrest brain injury, explores reasons for previous failure to translate preclinical data to clinical practice, and outlines potential paths forward. Post-cardiac arrest brain injury is characterized by 4 distinct but overlapping phases: ischemic depolarization, reperfusion repolarization, dysregulation, and recovery and repair. Previous research has been challenging because of the limitations of laboratory models; heterogeneity in the patient populations enrolled; overoptimistic estimation of treatment effects leading to suboptimal sample sizes; timing and route of intervention delivery; limited or absent evidence that the intervention has engaged the mechanistic target; and heterogeneity in postresuscitation care, prognostication, and withdrawal of life-sustaining treatments. Future trials must tailor their interventions to the subset of patients most likely to benefit and deliver this intervention at the appropriate time, through the appropriate route, and at the appropriate dose. The complexity of post-cardiac arrest brain injury suggests that monotherapies are unlikely to be as successful as multimodal neuroprotective therapies. Biomarkers should be developed to identify patients with the targeted mechanism of injury, to quantify its severity, and to measure the response to therapy. Studies need to be adequately powered to detect effect sizes that are realistic and meaningful to patients, their families, and clinicians. Study designs should be optimized to accelerate the evaluation of the most promising interventions. Multidisciplinary and international collaboration will be essential to realize the goal of developing effective therapies for post-cardiac arrest brain injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38934122/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38934122</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001219>10.1161/CIR.0000000000001219</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38934122</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Gavin D Perkins</dc:creator>
<dc:creator>Robert Neumar</dc:creator>
<dc:creator>Cindy H Hsu</dc:creator>
<dc:creator>Karen G Hirsch</dc:creator>
<dc:creator>Anders Aneman</dc:creator>
<dc:creator>Lance B Becker</dc:creator>
<dc:creator>Keith Couper</dc:creator>
<dc:creator>Clifton W Callaway</dc:creator>
<dc:creator>Cornelia W E Hoedemaekers</dc:creator>
<dc:creator>Shir Lynn Lim</dc:creator>
<dc:creator>William Meurer</dc:creator>
<dc:creator>Theresa Olasveengen</dc:creator>
<dc:creator>Mypinder S Sekhon</dc:creator>
<dc:creator>Markus Skrifvars</dc:creator>
<dc:creator>Jasmeet Soar</dc:creator>
<dc:creator>Min-Shan Tsai</dc:creator>
<dc:creator>Bhuma Vengamma</dc:creator>
<dc:creator>Jerry P Nolan</dc:creator>
<dc:creator>International Liaison Committee on Resuscitation</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Improving Outcomes After Post-Cardiac Arrest Brain Injury: A Scientific Statement From the International Liaison Committee on Resuscitation</dc:title>
<dc:identifier>pmid:38934122</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001219</dc:identifier>
</item>
<item>
<title>Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38934111/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The COORDINATE-Diabetes intervention successfully improved delivery of evidence-based care, regardless of sex, race, or ethnicity. Widespread dissemination of this intervention could improve equitable health care quality, particularly among women and minority communities who are frequently underrepresented in clinical trials.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 27. doi: 10.1161/CIRCULATIONAHA.124.068962. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Results from the COORDINATE-Diabetes trial demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based medical therapies to participants with type 2 diabetes and atherosclerotic cardiovascular disease. This secondary analysis assessed whether intervention success was consistent across sex, race, and ethnicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: COORDINATE-Diabetes, a cluster randomized trial, recruited participants from 43 US cardiology clinics (20 randomized to intervention and 23 randomized to usual care). The primary outcome was the proportion of participants prescribed all 3 groups of evidence-based therapy (high-intensity statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide 1 receptor agonist) at last trial assessment (6 to 12 months). In this prespecified analysis, mixed-effects logistic regression models were used to assess the outcome by self-reported sex, race, and ethnicity in the intervention and usual care groups, with adjustment for baseline characteristics, medications, comorbidities, and site location.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1045 participants with type 2 diabetes and atherosclerotic cardiovascular disease, the median age was 70 years, 32% were female, 16% were Black, and 9% were Hispanic. At the last trial assessment, there was an absolute increase in the proportion of participants prescribed all 3 groups of evidence-based therapy in women (36% versus 15%), Black participants (41% versus 18%), and Hispanic participants (46% versus 18%) with the intervention compared with usual care, with consistent benefit across sex (male versus female; <i>P</i><sub>interaction</sub>=0.44), race (Black versus White; <i>P</i><sub>interaction</sub>=0.59), and ethnicity (Hispanic versus Non-Hispanic; <i>P</i><sub>interaction</sub>= 0.78).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The COORDINATE-Diabetes intervention successfully improved delivery of evidence-based care, regardless of sex, race, or ethnicity. Widespread dissemination of this intervention could improve equitable health care quality, particularly among women and minority communities who are frequently underrepresented in clinical trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT03936660.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38934111/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38934111</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068962>10.1161/CIRCULATIONAHA.124.068962</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38934111</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Manasi Tannu</dc:creator>
<dc:creator>Lisa Kaltenbach</dc:creator>
<dc:creator>Neha J Pagidipati</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>Vanita R Aroda</dc:creator>
<dc:creator>Rodica Pop-Busui</dc:creator>
<dc:creator>Nitin Kondamudi</dc:creator>
<dc:creator>Hussein R Al-Khalidi</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Matthew A Cavender</dc:creator>
<dc:creator>Adam J Nelson</dc:creator>
<dc:creator>Julienne Kirk</dc:creator>
<dc:creator>Ildiko Lingvay</dc:creator>
<dc:creator>Melissa Magwire</dc:creator>
<dc:creator>Caroline Regina Richardson</dc:creator>
<dc:creator>Laura Webb</dc:creator>
<dc:creator>Monica Leyva</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Alana Washington</dc:creator>
<dc:creator>Jonathan Pak</dc:creator>
<dc:creator>Tanya Gaynor</dc:creator>
<dc:creator>Waqar Khan</dc:creator>
<dc:creator>Patrick Weston</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Jennifer Green</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial</dc:title>
<dc:identifier>pmid:38934111</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068962</dc:identifier>
</item>
<item>
<title>Global epidemiology of heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38926611/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>Heart failure (HF) is a heterogeneous clinical syndrome marked by substantial morbidity and mortality. The natural history of HF is well established; however, epidemiological data are continually evolving owing to demographic shifts, advances in treatment and variations in access to health care. Although the incidence of HF has stabilized or declined in high-income countries over the past decade, its prevalence continues to increase, driven by an ageing population, an increase in risk factors,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 26. doi: 10.1038/s41569-024-01046-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure (HF) is a heterogeneous clinical syndrome marked by substantial morbidity and mortality. The natural history of HF is well established; however, epidemiological data are continually evolving owing to demographic shifts, advances in treatment and variations in access to health care. Although the incidence of HF has stabilized or declined in high-income countries over the past decade, its prevalence continues to increase, driven by an ageing population, an increase in risk factors, the effectiveness of novel therapies and improved survival. This rise in prevalence is increasingly noted among younger adults and is accompanied by a shift towards HF with preserved ejection fraction. However, disparities exist in our epidemiological understanding of HF burden and progression in low-income and middle-income countries owing to the lack of comprehensive data in these regions. Therefore, the current epidemiological landscape of HF highlights the need for periodic surveillance and resource allocation tailored to geographically vulnerable areas. In this Review, we highlight global trends in the burden of HF, focusing on the variations across the spectrum of left ventricular ejection fraction. We also discuss evolving population-based estimates of HF incidence and prevalence, the risk factors for and aetiologies of this disease, and outcomes in different geographical regions and populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38926611/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38926611</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01046-6>10.1038/s41569-024-01046-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38926611</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Izza Shahid</dc:creator>
<dc:creator>Ahmed Bennis</dc:creator>
<dc:creator>Amina Rakisheva</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Global epidemiology of heart failure</dc:title>
<dc:identifier>pmid:38926611</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01046-6</dc:identifier>
</item>
<item>
<title>Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925729/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>Artificial intelligence (AI) has the potential to transform every facet of cardiovascular practice and research. The exponential rise in technology powered by AI is defining new frontiers in cardiovascular care, with innovations that span novel diagnostic modalities, new digital native biomarkers of disease, and high-performing tools evaluating care quality and prognosticating clinical outcomes. These digital innovations promise expanded access to cardiovascular screening and monitoring,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):97-114. doi: 10.1016/j.jacc.2024.05.003.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Artificial intelligence (AI) has the potential to transform every facet of cardiovascular practice and research. The exponential rise in technology powered by AI is defining new frontiers in cardiovascular care, with innovations that span novel diagnostic modalities, new digital native biomarkers of disease, and high-performing tools evaluating care quality and prognosticating clinical outcomes. These digital innovations promise expanded access to cardiovascular screening and monitoring, especially among those without access to high-quality, specialized care historically. Moreover, AI is propelling biological and clinical discoveries that will make future cardiovascular care more personalized, precise, and effective. The review brings together these diverse AI innovations, highlighting developments in multimodal cardiovascular AI across clinical practice and biomedical discovery, and envisioning this new future backed by contemporary science and emerging discoveries. Finally, we define the critical path and the safeguards essential to realizing this AI-enabled future that helps achieve optimal cardiovascular health and outcomes for all.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925729/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38925729</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.003>10.1016/j.jacc.2024.05.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925729</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Rohan Khera</dc:creator>
<dc:creator>Evangelos K Oikonomou</dc:creator>
<dc:creator>Girish N Nadkarni</dc:creator>
<dc:creator>Jessica R Morley</dc:creator>
<dc:creator>Jenna Wiens</dc:creator>
<dc:creator>Atul J Butte</dc:creator>
<dc:creator>Eric J Topol</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38925729</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.003</dc:identifier>
</item>
<item>
<title>Lessons for Cardiovascular Clinical Investigators: The Tumultuous 2,500-Year Journey of Physicians Who Ignited Our Fire</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925728/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>Whereas medical practice stems from Hippocrates, cardiovascular science originates with Aristotle. The Hippocratic philosophy was championed by Galen (129-216 CE), whose advocacy of a tripartite soul found favor in the early Christian Church. In contrast, Aristotle's works were banned as heresy by ecclesiastical authority, only to survive and prosper in the Islamic Golden Age (775-1258 CE). Galen theorized that the circulation consisted of separate venous and arterial systems. Blood was produced...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):78-96. doi: 10.1016/j.jacc.2024.03.420.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Whereas medical practice stems from Hippocrates, cardiovascular science originates with Aristotle. The Hippocratic philosophy was championed by Galen (129-216 CE), whose advocacy of a tripartite soul found favor in the early Christian Church. In contrast, Aristotle's works were banned as heresy by ecclesiastical authority, only to survive and prosper in the Islamic Golden Age (775-1258 CE). Galen theorized that the circulation consisted of separate venous and arterial systems. Blood was produced in the liver and traveled centrifugally through veins. When arriving in the right ventricle, venous blood passed through tiny pores in the ventricular septum into the left ventricle, where it became aerated by air passing from the lungs through the pulmonary veins to the left side of the heart. Following arrival at distal sites, arterial blood disappeared, being consumed by the tissues, requiring that the liver needed to continually synthesize new blood. The heart was viewed as a sucking organ, and the peripheral pulse was deemed to result from changes in arterial tone, rather than cardiac systole. Galen's framework remained undisputed and dominated medical thought for 1,300 years, but the reintroduction of Aristotelian principles from the Islamic world into Europe (through the efforts of the Toledo School of Translators) were nurtured by the academic freedom and iconoclastic environment uniquely cultivated at the University of Padua, made possible by Venetian rebellion against papal authority. At Padua, the work of Andreas Vesalius, Realdo Colombo, Hieronymus Fabricius ab Acquapendente, and William Harvey (1543-1628) methodically destroyed Galen's model, leading to the modern concept of a closed-ended circulation. Yet, due to political forces, Harvey was ridiculed, as was James Lind, who performed the first prospective controlled trial, involving citrus fruits for scurvy (1747); it took nearly 50 years for his work to be accepted. Even the work of William Withering (1785), the father of cardiovascular pharmacology, was tarnished by professional jealously and the marketing campaign of a pharmaceutical company. Today's cardiovascular investigators should understand that major advances are routinely derided by the medical establishment for political or personal reasons; and it may take decades or centuries for important work to be accepted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38925728</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.420>10.1016/j.jacc.2024.03.420</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925728</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lessons for Cardiovascular Clinical Investigators: The Tumultuous 2,500-Year Journey of Physicians Who Ignited Our Fire</dc:title>
<dc:identifier>pmid:38925728</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.420</dc:identifier>
</item>
<item>
<title>ALARA in Atrial Fibrillation: Redefining Ablation Success</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925727/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):75-77. doi: 10.1016/j.jacc.2024.05.011. Epub 2024 May 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925727/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38925727</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.011>10.1016/j.jacc.2024.05.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925727</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter Hanna</dc:creator>
<dc:creator>Carlos Macias</dc:creator>
<dc:creator>Eric Buch</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>ALARA in Atrial Fibrillation: Redefining Ablation Success</dc:title>
<dc:identifier>pmid:38925727</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.011</dc:identifier>
</item>
<item>
<title>The FDA and the Cardiovascular Community</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925726/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):124-129. doi: 10.1016/j.jacc.2024.05.013.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925726/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38925726</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.013>10.1016/j.jacc.2024.05.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925726</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Haider J Warraich</dc:creator>
<dc:creator>Robert M Califf</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The FDA and the Cardiovascular Community</dc:title>
<dc:identifier>pmid:38925726</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.013</dc:identifier>
</item>
<item>
<title>Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):121-123. doi: 10.1016/j.jacc.2024.04.044.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38925725</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.044>10.1016/j.jacc.2024.04.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925725</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Eldad Ben-Chetrit</dc:creator>
<dc:creator>Mark Nidorf</dc:creator>
<dc:creator>Rodney Falk</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule?</dc:title>
<dc:identifier>pmid:38925725</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.044</dc:identifier>
</item>
<item>
<title>The Next Era of JACC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925724/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):118-120. doi: 10.1016/j.jacc.2024.05.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925724/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38925724</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.023>10.1016/j.jacc.2024.05.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925724</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Next Era of JACC</dc:title>
<dc:identifier>pmid:38925724</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.023</dc:identifier>
</item>
<item>
<title>The Editorship of the Journal of the American College of Cardiology: Passing the Torch</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925723/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628180826&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):115-117. doi: 10.1016/j.jacc.2024.04.045.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925723/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628180826&v=2.18.0.post9+e462414">38925723</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.045>10.1016/j.jacc.2024.04.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925723</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Editorship of the Journal of the American College of Cardiology: Passing the Torch</dc:title>
<dc:identifier>pmid:38925723</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.045</dc:identifier>
</item>





























</channel>
</rss>